



Office de la Propriété

Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2371577 A1 2000/11/09

(21) 2 371 577

(12) DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/04/07  
(87) Date publication PCT/PCT Publication Date: 2000/11/09  
(85) Entrée phase nationale/National Entry: 2001/10/24  
(86) N° demande PCT/PCT Application No.: US 2000/009415  
(87) N° publication PCT/PCT Publication No.: 2000/066718  
(30) Priorité/Priority: 1999/04/30 (09/303,208) US

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C12N 9/64, C07K 16/40, C12N 5/12,  
G01N 33/68

(71) Demandeurs/Applicants:  
HYBRITECH INCORPORATED, US;  
BAYLOR COLLEGE OF MEDICINE, US

(72) Inventeurs/Inventors:  
SLAWIN, KEVIN, US;  
WOLFERT, ROBERT, US;  
MIKOLAJCZYK, STEPHEN, US;  
RITTENHOUSE, HARRY, US;  
WANG, TANG, US

(74) Agent: MACRAE & CO.

(54) Titre : FORMES DE L'ANTIGENE PROSTATIQUE SPECIFIQUE (APS) SPECIFIQUES A L'HYPERPLASIE  
PROSTATIQUE BENIGNE (HPB) ET PROCEDES DE LEUR UTILISATION

(54) Title: FORMS OF PROSTATE SPECIFIC ANTIGEN (PSA) SPECIFIC FOR BENIGN PROSTATIC HYPERPLASIA  
(BPH) AND METHODS OF USING SUCH

(57) Abrégé/Abstract:

A substantially pure and isolated novel form of prostate specific antigen (PSA) is provided. The novel form of PSA of the present invention comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA. Preferably, the novel form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146. More preferably, the form of PSA contains at least two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA. The novel forms of PSA exist at an elevated level in patients suspected of having benign prostatic hyperplasia (BPH) and therefore may be used as a serum mark or an immunohistological marker to help distinguish BPH from prostate cancer. Antibodies recognizing the novel forms of PSA and immunoassays that detect and determine the novel forms of PSA of the present invention in a sample are also provided. Further provided are a kit and a method for detecting the novel forms of PSA for aiding in the differentiation of prostate cancer from BPH.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 9/64, C07K 16/40, C12N 5/12, G01N 33/68</b>		A1	(11) International Publication Number: <b>WO 00/66718</b> (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/09415		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 7 April 2000 (07.04.00)			
(30) Priority Data: 09/303,208 30 April 1999 (30.04.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicants: HYBRITECH INCORPORATED [US/US]; 7330 Carroll Road, P.O. Box 269006, San Diego, CA 92121 (US). BAYLOR COLLEGE OF MEDECINE [US/US]; Stewart, N., Davis, BCM Technologies, Medical Tower Building, 1709 Dryden Road, Suite 901, Houston, TX 77030 (US).			
(72) Inventors: MIKOLAJCZYK, Stephen; 4052 Conrad Avenue, San Diego, CA 92117 (US). WANG, Tang; 12671 Acacia Terrace, Poway, CA 92064 (US). RITTENHOUSE, Harry; 13972 Mercado Drive, Del Mar, CA 92014 (US). WOLFERT, Robert; 10495 Canyon Lake Drive, San Diego, CA 92131 (US). SLAWIN, Kevin; 2336 Underwood Boulevard, Houston, TX 77030 (US).			
(74) Agents: MAY, William, H. et al.; Beckman Coulter, Inc., 4300 N. Harbor Boulevard, P.O. Box 3100, Fullerton, CA 92834-3100 (US).			

(54) Title: FORMS OF PROSTATE SPECIFIC ANTIGEN (PSA) SPECIFIC FOR BENIGN PROSTATIC HYPERPLASIA (BPH) AND METHODS OF USING SUCH

(57) Abstract

A substantially pure and isolated novel form of prostate specific antigen (PSA) is provided. The novel form of PSA of the present invention comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA. Preferably, the novel form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146. More preferably, the form of PSA contains at least two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA. The novel forms of PSA exist at an elevated level in patients suspected of having benign prostatic hyperplasia (BPH) and therefore may be used as a serum mark or an immunohistological marker to help distinguish BPH from prostate cancer. Antibodies recognizing the novel forms of PSA and immunoassays that detect and determine the novel forms of PSA of the present invention in a sample are also provided. Further provided are a kit and a method for detecting the novel forms of PSA for aiding in the differentiation of prostate cancer from BPH.

FORMS OF PROSTATE SPECIFIC ANTIGEN (PSA) SPECIFIC FOR BENIGN PROSTATIC HYPERPLASIA (BPH) AND METHODS OF USING SUCH

5 Background of the Invention

Field of the Invention

The invention relates generally to prostate specific antigen (PSA) and specifically to new forms of PSA that are specific for benign prostatic hyperplasia and methods of using the new forms of PSA.

10 Description of the Prior Art

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this 15 application, preceding the claims.

Prostate cancer is the most frequently diagnosed cancer in American males. Prostate specific antigen (PSA) has been widely used as a reliable prognostic marker in the management of patients with prostate cancer (1-3). PSA is a member of the human kallikrein family of serine proteases (extensively reviewed in (4)). It is a serine 20 endopeptidase with chymotrypsin-like enzymatic activity. The mature form of PSA has isoleucine as the N-terminal and 237 amino acid residues with a molecular mass of 28,400 D (5; 6).

PSA exists in the serum as the free form of PSA but the majority of the PSA is in a complex with  $\alpha$ 1-antichymotrypsin (ACT). It is generally accepted that the free PSA in

serum is enzymatically inactive. PSA is a serine protease which is capable of complex formation with serum protease inhibitors. Human serum contains high levels of ACT and  $\alpha_2$ macroglobulin, both of which have been shown to complex with PSA (8). 70-95% of the PSA in serum which can be detected by immunoassay is in a complex with ACT. The 5 remainder is non-complexed, free PSA (9; 10).

More recently it has been demonstrated that the level of free or non-complexed PSA in serum can improve the discrimination of prostate cancer from BPH (9-11). An elevated ratio of free PSA to total PSA (free plus complexed PSA) is more highly correlated with BPH. The reasons for the presence of free PSA in serum has therefore 10 become the subject of intensive investigation.

Studies with PSA purified from seminal plasma have shown that about 30% of the PSA does not form a complex with ACT. This fraction of PSA contains an internal peptide bond cleavage at Lysine 145 which renders it inactive (8-10). A more detailed analysis of the inactive forms of PSA from seminal plasma revealed PSA clipped at both 15 Lysine 145 and Arginine 85, in addition to a fraction of PSA which was not clipped but which did not form a complex with ACT (12).

One of the earliest investigations for purifying and characterizing PSA from seminal plasma reported the presence of internal clips at residues Arginine 85, Lysine 148 and Lysine 185 (5). However, the relative proportion and significance of these clips was 20 not determined at that time. Subsequent studies of inactive PSA, as cited above, have focused almost exclusively on the clip at Lysine 145, since this is the predominant clip in seminal plasma PSA and does in fact render PSA inactive. There is no suggestion in these studies that the Lysine 145 clip represents anything more than a random physiological cleavage which occurs some time after PSA expression. It is suggested that this clip could

account for the presence of free PSA in serum. There is, however, no evidence that PSA in seminal plasma is representative of PSA found in serum, since serum PSA is due to the retrograde release of PSA from prostate tissues (4).

PSA has also been isolated from BPH tissue in the prostate in order to determine  
5 whether this form of PSA was different from seminal plasma PSA (13). PSA from BPH tissue was found to be less enzymatically active than seminal plasma PSA and to contain additional clips, including clips after Ile1, His54, Phe57 and Lys146. The characterization of PSA from BPH tissue had three major conclusions: 1) the BPH PSA is more clipped than seminal plasma PSA; 2) the BPH PSA is less enzymatically active than seminal  
10 plasma PSA; and 3) BPH PSA contains some unusual clips not found in seminal plasma PSA.

The limitation of this approach is that BPH tissue PSA was not compared to other matched prostate tissues but rather to seminal plasma PSA. It was not established whether BPH PSA was less enzymatically active than, or different from, other prostate tissue PSA.  
15 This is an important experimental consideration, since the preparation of PSA from tissues could include proteases from tissues not found in seminal plasma, or vice versa. In theory, PSA prepared from any prostate tissue might be more inactive than seminal plasma PSA, due merely to the presence of selective endogenous proteolysis, or proteolysis during tissue homogenization and PSA purification.

20 The major limitation of a PSA test is its lack of specificity to distinguish between benign prostatic hyperplasia (BPH) and prostate cancer (7). Elevated levels of PSA in the blood are symptomatic of prostate disease, which is primarily manifested as either BPH or prostate cancer. However, levels in the range of 4-10 ng PSA per ml of serum make BPH difficult to distinguish from prostate cancer without additional tests, such as a digital rectal

exam and prostate needle biopsy. Clearly, a need exists to develop a serum marker that is specific for BPH. A need also exists to develop a diagnostic method that may be used to distinguish BPH from prostate cancer.

#### Summary of the Invention

5 The present invention takes a different approach than previous approaches by other investigators in that the present invention has focused exclusively on prostate tissues as the source of variable forms of PSA in serum. In order to determine what molecular forms of PSA are present in the prostate, the present invention examined three different types of prostate tissue: 1) non-cancerous peripheral zone (PZ-N) tissue; 2) cancerous PZ tissue  
10 containing at least 80% tumor (PZ-C); and 3) non-cancerous transitional zone (TZ) tissue. It is the TZ which becomes hyperplastic in patients with BPH. In contrast, most cancers are found in the PZ. The present invention discovers that different forms of PSA are present in different types of tissues.

The present invention is based on the unexpected discovery of novel forms of PSA  
15 existing at an elevated level in human prostate transition zone (TZ) which contains the benign prostatic hyperplasia tissue. One novel form of PSA in the present invention includes at least one clip at Lysine 182 of the amino acid sequence of a mature form of PSA. A novel form of PSA of the present invention may also include an additional one or  
20 more clips at Ile 1, Lys 145 and Lys 146 of the amino acid sequence of a mature form of PSA. The novel forms of PSA have a unique conformation of their own and can be separated from a mature form of PSA or other forms of PSA by high performance hydrophobic interaction chromatography (HIC-HPLC). It is the discovery of the present invention that the novel forms of PSA exist at an elevated level in BPH tissues. Therefore,

the novel forms of PSA of the present invention may be used as a serum marker or an immunohistological marker to distinguish BPH tissues.

Accordingly, one aspect of the present invention provides a substantially pure and isolated form of prostate specific antigen (PSA) comprising at least one clip at Lysine 182 5 of the amino acid sequence of a mature form of PSA. The form of PSA may also include an additional one or more clips at Ile 1, Lys 145 and Lys 146 of the amino acid sequence of a mature PSA. In one embodiment, the novel form of PSA of the present invention consists of two clips at Lys 145 and Lys 182 of amino acid sequence of a mature form of PSA.

10 Another aspect of the present invention provides an antibody that is preferentially reactive with novel forms of PSA of the present invention. The antibody may be a monoclonal or polyclonal antibody. Immunogens, cell lines and methods of making the preferential reactive antibodies are also provided.

15 A further aspect of the present invention provides a method of detecting or determining in a sample a novel form of PSA of the present invention. The method includes the steps of:

(a) contacting an amount of an agent which specifically binds to the form of PSA to be detected with the sample under a condition that allows the formation of a binary complex comprising the agent and the form of PSA; and  
20 (b) detecting or determining the presence or amount of the complex.

In accordance with embodiments of the present invention, the sample may be a human physiological fluid or a tissue specimen. The agent may be an antibody, and the antibody may be labeled or able to bind to a label, or the antibody may be bound to a solid phase.

Yet another aspect of the present invention provides a diagnostic kit for detecting or determining in a sample a novel form of PSA of the present invention. Also provided is a diagnostic method for distinguishing BPH tissues. A competitive immunoassay is also provided for detecting a novel form of PSA of the present invention.

5 The invention is defined in its fullest scope in the appended claims and is described below in its preferred embodiments.

### Description of the Figures

The above-mentioned and other features of this invention and the manner of obtaining them will become more apparent, and will be best understood, by reference to the following description, taken in conjunction with the accompanying drawings. These 5 drawings depict only a typical embodiment of the invention and do not therefore limit its scope. They serve to add specificity and detail, in which:

Figure 1 is a high-performance hydrophobic interaction chromatographic (HIC-HPLC) profile of immunoaffinity-purified PSA isolated from prostate tissues.

Figure 2 is an HIC-HPLC profile of PSA purified from TURP (transurethral 10 resection of the prostate) prostate tissue.

Figure 3 is an HIC-HPLC profile of PSA purified from prostate tissue.

Figure 4, panel A is an HIC-HPLC profile of PSA purified from prostate tissue.

The arrows indicate where fractions were collected. Panel B is an aliquot of each fraction in panel A re-run by HIC-HPLC.

15 Figure 5 is a histogram showing the N-terminal sequence analysis of the two peaks in Figure 4. The histogram shows the percentage of the total PSA clipped at each site indicated.

Figure 6 is an HIC-HPLC profile of the PSA purified from pooled seminal plasma.

Figure 7 is an HIC-HPLC profile of different types of PSA. Panel A is inactive 20 seminal plasma PSA, defined as that fraction of PSA which does not react with ACT.

Panel B is HIC-HPLC purified 10 min PSA. This is the 10 min peak purified from panel C. Panel C is an HIC-HPLC profile of immunoaffinity purified whole seminal plasma PSA. Panel D is an HIC-HPLC purified BPSA from whole seminal plasma PSA. This is the 8 min peak from panel C.

Figure 8 is the N-terminal sequence analysis of the PSA peaks in Figure 7. The histogram shows the percentage of the total PSA which is clipped at each of the indicated sites.

Figure 9 is the HIC-HPLC profile of PSA before and after incubation with trypsin.

5 Figure 10 is the N-terminal sequencing of the samples in Figure 9.

Figure 11 is a summary histogram of N-terminal sequencing of all the major types of purified PSA and BPSA.

Figure 12 is a competition assay using different types of PSA.

Figure 13 shows the results of a competition assay comparing BPSA to different  
10 types of PSA obtained after trypsin treatment.

Figure 14 is the linear sequence of amino acids for PSA. The arrows show the sites of internal peptide bond cleavage which are described in the text.

Figure 15 is a plot which compares monoclonal antibody reactivity of PS2C109 to purified BPSA and PSA.

15 Figure 16 is a box plot showing increased %BPSA in those transitional zone prostate tissues with nodular development symptomatic of BPH.

Detailed Description of the Invention

One aspect of the present invention provides a substantially pure and isolated form of prostate specific antigen (PSA) comprising at least one clip at Lysine 182 of the amino acid sequence of a mature form of PSA. The term "substantially pure" as used herein 5 refers to the form of PSA that is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. The substantially pure form of PSA of the present invention will yield a single major peak by high-performance hydrophobic interaction chromatography (HIC-HPLC), a chromatographic technique that is well known in the art. The purity of the specific form of PSA can also be determined by 10 amino-terminal amino acid sequence analysis.

A mature form of PSA has 237 amino acid residues with a molecular mass of 28,400 D (6) and the amino acid sequence is fully described in references (4). The sequence of the matured form of PSA is shown in Figure 14. A novel form of PSA discovered by the present invention has at least one clip at Lysine 182 of the amino acid 15 sequence of a mature form of PSA. In other words, a novel form of PSA of the present invention has the same amino acid sequence of a mature form of PSA, except that the polypeptide chain of the PSA of the present invention has been hydrolyzed between residues 182 and 183. In accordance with embodiments of the present invention, a novel form of PSA of the present invention may also include additional one or more clips at Ile 20 1, Lys 145 and Lys 146 of the amino acid sequence of a mature PSA. In one embodiment of the present invention, a novel form of PSA of the present invention consists of two clips at Lys 145 and Lys 182.

It is a discovery of the present invention that the clip at Lys 182, and particularly the clips at Lys 145 and Lys 182 of a novel form of PSA of the present invention, has

significantly changed the conformation of the novel forms of PSA, such that they elute differently from the mature form or other forms of PSA by HIC-HPLC. As a consequence, a novel form of PSA of the present invention can be separated from the mature form or other forms of PSA by HIC-HPLC. Hydrophobic interaction 5 chromatography is sensitive to changes in the surface hydrophobicity of proteins caused by protein folding changes (14). Novel forms of PSA of the present invention yield one major peak by HIC-HPLC.

A novel form of PSA of the present invention exists at an elevated level in the transition zone of BPH tissue compared to peripheral zone cancer and non-cancer prostate 10 tissues. The prostate is composed of three zones: the central zone, the peripheral zone (PZ) and the transition zone (TZ). The PZ comprises about 70% of the volume of a normal prostate, while the central zone and TZ are about 25% and 5%, respectively. All 15 three zones are well defined in the art. (See *Biopsy Pathology of the Prostate*, David G. Bostwick and Paul A. Dundore, published by Chapman & Hall USA, 115 Fifth Ave., New York, NY, 10003.) Briefly, the TZ is characterized by small, simple glands embedded in a compact stroma, whereas the PZ is characterized by small glands embedded in a loose stroma. The TZ tissue forms a distinctive boundary with the PZ. The PZ and TZ are the 20 zones of primary interest, since cancer is localized primarily to the PZ, while BPH is the result of tissue enlargement of the TZ. With extensive BPH, the TZ grows to several times the volume of other prostate zones. The TZ tissue surrounds the proximal prostate urethra, which is the reason that restricted urinary flow is a symptom of enlarged TZ resulting from 25 BPH.

For the purpose of the present invention, the level of a novel form of PSA is elevated if the percentage of the novel form of PSA compared to total PSA is higher than

the percentage of the novel form of PSA occurring in peripheral zone cancer and non-cancer prostate tissues. In accordance with one embodiment of the present invention, PSA extracted from BPH tissues contains from 5 to 30% of novel forms of PSA of the present invention. The novel forms of PSA are lower or absent in peripheral zone cancer and non-cancer prostate tissues, as well as seminal plasma. Since it is the TZ which becomes hyperplastic in patients with BPH, it is believed that novel forms of PSA of the present invention may be specific for BPH; and, therefore, novel forms of PSA of the present invention are also called BPSA for the purpose of the present invention.

In addition, it is the discovery of the present invention that the novel form of PSA is inactive, i.e., it lacks chymotrypsin-like enzymatic activity and therefore is present in serum as free PSA, not as PSA antichymotrypsin complex. For the purpose of the present invention, a free PSA is a PSA that is not complexed as part of an antichymotrypsin complex.

Novel forms of PSA of the present invention may be isolated from tissues or seminal plasma or prepared by *in vitro* trypsin treatment by methods described herein or otherwise known in the art. Novel forms of PSA of the present invention may be characterized and used for antibody development. It is a discovery of the present invention that the clip at Lys 182 of a novel form of PSA of the present invention may result in conformational changes which alter some epitopes of PSA. As a consequence, novel forms of PSA of the present invention may be used as antigens to generate monoclonal antibodies that preferentially recognize novel forms of PSA of the present invention over other forms of PSA.

Accordingly, one aspect of the present invention provides an antibody that is specifically immunoreactive with and binds to a novel form of PSA of the present

invention. The term "specifically immunoreactive" as used herein indicates that the antibodies of the present invention preferentially recognize and bind to the novel form of PSA of the present invention over other forms of PSA, such as other clipped or non-clipped mature forms of PSA. The term "preferentially recognize and bind" as used herein 5 means that the antibodies of the present invention bind more tightly to the novel form of PSA of the present invention than to other forms of PSA under the same conditions. The cross-reactivity of antibodies of the present invention to other forms of PSA is relatively low. In accordance with embodiments of the present invention, the cross-reactivity of antibodies of the present invention to other forms of PSA is preferably less than about 10 10%, and most preferably less than about 1%.

An antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations, is provided. Monoclonal antibodies are made from an antigen containing the novel form of PSA of the present invention or fragments thereof by methods well known in the art (E. 15 Harlow et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In general, this method involves preparing an antibody-producing fused cell line, e.g., from primary spleen cells fused with a compatible continuous line of myeloma cells, growing the fused cells either in mass culture or in an animal species from which the myeloma cell line used was derived or is compatible. Such antibodies offer many 20 advantages in comparison to those produced by inoculation of animals, as they are highly specific and sensitive and relatively "pure" immunochemically. Immunologically active fragments of antibodies are also within the scope of the present invention, e.g., the f(ab) fragment, as are partially humanized monoclonal antibodies.

If desired, polyclonal antibodies can be further purified, for example, by binding to elution from a matrix to which a polypeptide or a peptide to which the antibodies were raised is bound. Those skilled in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as 5 monoclonal antibodies. (See, for example, Coligan et al., Unit 9, *Current Protocols in Immunology*, Wiley Interscience, 1991, incorporated by reference.)

The term "antibody" as used in this invention includes intact molecules as well as fragments thereof, such as Fab,  $F(ab')_2$  and Fv, which are capable of binding the epitopic determinant. These antibody fragments retain some ability to selectively bind with its 10 antigen or receptor and are defined as follows:

- (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule can be produced by digestion of the whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
- (2) Fab', the fragment of an antibody molecule that can be obtained by treating 15 the whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain — two Fab' fragments are obtained per antibody molecule;
- (3)  $F(ab')_2$ , the fragment of the antibody that can be obtained by treating the whole antibody with the enzyme pepsin without subsequent reduction —  $F(ab')_2$  is a dimer of two Fab' fragments held together by two disulfide bonds;
- (4) Fv, defined as a genetically engineered fragment containing the variable 20 region of the light chain and the variable region of the heavy chain expressed as two chains; and

(5) Single chain antibody ("SCA"), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of making these fragments are known in the art. (See, for example,

5 Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1988), incorporated herein by reference.)

As used in this invention, the term "epitope" means any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar 10 side chains, and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.

It is a discovery of the present invention that the novel forms of the present invention include epitopes that may be preferentially recognized by monoclonal antibodies that do not recognize or recognize poorly the other forms of PSA. Accordingly, one 15 embodiment of the present invention provides a method of making monoclonal antibodies that preferentially recognize the novel forms of PSA of the present invention. The method includes steps of:

(a) providing at least one blocking antibody against both a novel form of PSA of the present invention and another form of PSA;

20 (b) binding the blocking antibody to the novel form of PSA to form an immunogen;

(c) immunizing a mouse with the immunogen; and

(d) producing monoclonal antibodies from the immunized mouse by employing a monoclonal antibody technique, wherein the monoclonal antibodies preferentially bind to the novel form.

For the purpose of the present invention, a “blocking antibody” is an antibody that

5 recognizes at least one of the epitopes that are commonly shared by a novel form of PSA and another form of PSA, the binding of which to the novel form of PSA would make the unique antigenic site of the novel form of PSA more immunodominant such that the novel form of PSA with the blocking antibody can be better used as an immunogen for

10 producing monoclonal antibodies that preferentially bind to the novel form of PSA than other forms of PSA. Preferably, blocking antibodies are those that bind to epitopes that may be distant from the unique antigenic sites of novel forms of PSA. In accordance with

15 embodiments of the present invention, multiple blocking antibodies that bind to both a novel form of PSA of the present invention and another form of free PSA to a similar extent may be used to generate an immunogen of the present invention. Examples of such antibodies include, not are not limited to, PSM773, PSJ206, PS1R163, and the like. The

block 20  
15  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
62

that is immunized with an immunogen of the present invention. Examples of the techniques are described above and under Examples below.

The present invention also provides an immunogen that is capable of eliciting a monoclonal antibody which preferentially binds to a novel form of PSA of the present invention than other forms of free PSA. In accordance with embodiments of the present invention, an immunogen of the present invention may include a novel form of PSA of the present invention and at least one blocking antibody that binds to both the novel form of PSA and another form of free PSA. According to embodiments of the present invention, an immunogen of the present invention may include multiple blocking antibodies, provided that the binding of the blocking antibodies to the immunogen makes the unique antigenic site of the novel form of PSA immunodominant.

The present invention also provides a hybridoma cell line that is capable of producing a monoclonal antibody that preferentially binds a novel form of PSA of the present invention than other forms of free PSA. Examples of a hybridoma cell line of the present invention include, but are not limited to, cell lines that are capable of producing monoclonal antibodies PS2C109, PS2C501, PS2C634, PS2C807 and PS2C837.

The novel form of PSA of the present invention may be used as a serum marker for detecting BPH. It may also be used as an immunohistological marker to help distinguish BPH tissue from normal or cancer tissues. In accordance with the present invention, the novel form of PSA may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by *in vitro* immunoassay procedures. The determination of the novel form of PSA in a patient sample is of significant diagnostic utility and may be an indicator of, or correlate with, the progression of a drug treatment for a BPH patient.

Immunohistochemical methods for the detection of antigens in patient tissue

specimens are well known in the art and need not be described in detail herein. For example, methods for the immunohistochemical detection of antigens are generally described in Taylor, *Arch. Pathol. Lab. Med.* 102:113 (1978). Briefly, in the context of

5 the present invention, a tissue specimen obtained from a patient suspected of having a prostate-related problem is contacted with an antibody, preferably a monoclonal antibody, recognizing the novel form of PSA. The site at which the antibody is bound is thereafter determined by selective staining of the tissue specimen by standard immunohistochemical procedures. In one embodiment of the present invention, the tissue specimen is a tissue

10 specimen obtained from the prostate of a patient. The prostate tissue may be a normal prostate tissue, a cancer prostate tissue or a benign prostatic hyperplasia tissue.

Similarly, the general methods of the *in vitro* detection of antigenic substances in patient fluid samples by immunoassay procedures are also well known in the art and require no repetition herein. For example, immunoassay procedures are generally

15 described in Paterson et al., *Int. J. Can.* 37:659 (1986) and Burchell et al., *Int. J. Can.* 34:763 (1984). According to one embodiment of the present invention, an immunoassay for detecting the novel form of PSA of the present invention in a biological sample comprises the steps of: (a) contacting an amount of an agent which specifically binds to the form of PSA to be detected with the sample under a condition that allows the

20 formation of a binary complex comprising the agent and the form of PSA; and (b) detecting or determining the presence or amount of the complex as a measure of the amount of the novel form of PSA contained in the sample.

For the purpose of the present invention, the biological sample can be any human physiological fluid sample that contains the novel form of PSA of the present invention.

Examples of the human physiological fluid sample include, but are not limited to, serum, seminal fluid, urine and plasma.

For the purpose of the present invention, both monoclonal antibodies and polyclonal antibodies may be used as long as such antibodies possess the requisite 5 specificity for the antigen provided by the present invention. Preferably, monoclonal antibodies are used.

Monoclonal antibodies can be utilized in liquid phase or bound to a solid phase carrier. Monoclonal antibodies can be bound to many different carriers and used to determine the novel form of PSA of the present invention. Examples of well-known 10 carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetites. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Examples of insoluble carriers include, but are not limited to, a bead and a microtiter plate. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or 15 will be able to ascertain such under routine experimentation.

In addition, the monoclonal antibodies in these immunoassays can be detectably labeled in various ways. For example, monoclonal antibodies of the present invention can be coupled to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as 20 biotin, which reacts with avidin, or dinitrophenyl, pyridoxal and fluorescein, which can react with specific antihapten antibodies. In addition, monoclonal antibodies of the present invention can also be coupled with a detectable label such as an enzyme, radioactive isotope, fluorescent compound or metal, chemiluminescent compound or bioluminescent compound. Furthermore, the binding of these labels to the desired

molecule can be done using standard techniques common to those of ordinary skill in the art.

One of the ways in which the antibody can be detectably labeled is by linking it to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the 5 substrate in such a manner as to produce a chemical moiety which can be detected by, for example, spectrophotometric or fluorometric means (ELISA system). Examples of enzymes that can be used as detectable labels are horseradish peroxidase, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, 10 alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.

For increased sensitivity in the ELISA system, the procedures described can be modified using biotinylated antibodies reacting with avidin-peroxidase conjugates.

15 The amount of antigen can also be determined by labeling the antibody with a radioactive isotope. The presence of the radioactive isotope would then be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful are  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{51}\text{Cr}$ ,  $^{36}\text{Cl}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{75}\text{Se}$ ,  $^{111}\text{N}$ ,  $^{99}\text{mTc}$ ,  $^{67}\text{Ga}$  and  $^{90}\text{Y}$ .

20 Determination of the antigen is also possible by labeling the antibody with a fluorescent compound. When the fluorescently labeled molecule is exposed to light of the proper wave length, its presence can then be detected due to fluorescence of the dye. Among the most important fluorescent labeling compounds are fluorescein isothiocyanate,

rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

Fluorescence-emitting metal atoms such as Eu (europium), and other lanthanides, can also be used. These can be attached to the desired molecule by means of metal-5 chelating groups, such as DTPA or EDTA.

Another way in which the antibody can be detectably labeled is by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged immunoglobulin is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful 10 chemiluminescent labeling compounds are luminol, isoluminol, aromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may also be used as a label.

Bioluminescence is a special type of chemiluminescence which is found in biological systems and in which a catalytic protein increases the efficiency of the chemiluminescent 15 reaction. The presence of a bioluminescent molecule would be determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Qualitative and/or quantitative determinations of the novel form of PSA of the present invention in a sample may be accomplished by competitive or non-competitive 20 immunoassay procedures in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the monoclonal antibodies of the present invention can be done utilizing immunoassays which are run in either the forward, reverse or simultaneous modes, including immunohistochemical assays on physiological samples. Those skilled in

the art will know, or can readily discern, other immunoassay formats without undue experimentation.

The term "immunometric assay" or "sandwich immunoassay" includes a simultaneous sandwich, forward sandwich and reverse sandwich immunoassay. These 5 terms are well understood by those skilled in the art. Those skilled in the art will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.

In accordance with one embodiment of the present invention, the present invention 10 provides a competition method for detecting or determining in a sample of a human physiological fluid a novel form of PSA of the present invention. The method comprises:

- (a) providing an amount of purified antibody which specifically reacts with the form of PSA to be detected;
- (b) mixing the sample with a known amount of the form of PSA or an 15 immunoreactive subunit thereof to produce a mixed sample, wherein the known amount of the form of PSA is capable of binding to the purified antibody and is labeled with a detectable label;
- (c) contacting the antibodies with the mixed sample under a condition that allows immunological reaction to occur between the antibody and the form of PSA in the 20 sample and between the antibody and the labeled PSA;
- (d) separating the antibody from the mixed sample;
- (e) detecting or determining the presence or the amount of labeled PSA either bound to the antibody or remaining in the mixed sample; and

(f) determining from the result in step (e) the presence or the amount of the form of PSA in the sample.

One aspect of the present invention provides a diagnostic kit for detecting or determining in a sample a novel form of PSA of the present invention. The kit comprises 5 a known amount of an agent which specifically binds to the novel form of PSA, wherein the agent is detectably labeled or binds to a detectable label. For the purpose of the present invention, the sample may be a sample of human physiological fluid such as, but not limited to, serum, seminal plasma, urine or plasma. The sample may also be a tissue specimen coming from the prostate of a patient. The agent may be an antibody that 10 specifically binds to the novel form of PSA of the present invention. Preferably the agent is a monoclonal antibody, although a polyclonal antibody may also be used.

Another aspect of the present invention provides a diagnostic method for determining the presence or absence of benign prostate hyperplasia. The method comprises the steps of:

15 (a) contacting an amount of an agent which specifically binds to a novel form of PSA of the present invention with a sample obtained from a human containing the form of PSA under a condition that allows the formation of a binary complex comprising the agent and the form of PSA; and

(b) determining the amount of the complex in the sample and correlating the 20 amount of the complex to the presence or absence of benign prostatic hyperplasia in the human.

In one embodiment of the present invention, the sample may be a sample of human physiological fluid such as, but not limited to, serum, seminal plasma, urine, and plasma. In another embodiment of the present invention, the sample may be tissue specimen from

the prostate of a patient. For the purpose of the present invention, the agent may be an antibody that specifically recognizes a novel form of PSA of the present invention. The antibody may be a monoclonal antibody or a polyclonal antibody.

The following examples are intended to illustrate, but not to limit, the scope of the invention. While such examples are typical of those that might be used, other procedures known to those skilled in the art may alternatively be utilized. Indeed, those of ordinary skill in the art can readily envision and produce further embodiments, based on the teachings herein, without undue experimentation.

## EXAMPLES

Materials and MethodsIsolation of PSA from prostate tissue

Prostate tissue was frozen in liquid nitrogen and pulverized to a fine powder in a metal tissue pulverizer maintained in liquid nitrogen. For the PZ-N, PZ-C and TZ tissue samples, which ranged from 100-300 mg, the frozen tissue powder was homogenized in 3 mls of PBS containing a protease inhibitor cocktail (Complete, Boehringer Manheim) using a glass tissue homogenizer. The sample was then centrifuged to remove cell debris and the supernatant solution filtered through a 0.2 um membrane. Larger amounts of tissue were extracted as described above except that the tissue was homogenized in a 50 ml tube using a Polytron tissue homogenizer.

PSA was purified from the filtered supernatant solution by passage over an immunoaffinity column containing bound anti-PSA mAb, PSM773, at 5 mg per ml of resin. The column was washed with 40 volumes of PBS containing 0.1% reduced Triton-X100, and the PSA eluted with 100 mM glycine pH 2.5, containing 200 mM sodium chloride. The eluant was immediately neutralized with 10% vol/vol 1M Tris pH 8.0.

Preparation of BPSA in vitro

Processed, filtered seminal plasma was diluted 1:10 in PBS and passed over an immunoaffinity column with bound anti-PSA mAb, PSM773. The column was washed with 20 volumes of PBS containing 0.1% reduced Triton X100, and the PSA eluted with 100 mM glycine pH 2.5 containing 200 mM sodium chloride. The purified PSA was applied to HIC-HPLC as described below, and the 8 min BPSA peak and the 10 min PSA peak were collected separately. The PSA from the 10 min peak was dialyzed into 100 mM Tris, pH 8 and incubated with 1% w/w trypsin for 30 min at 37 C. The trypsin in the

mixture was inactivated by addition of a mass of aprotinin equal to twice the added trypsin. The incubation mixture was applied to HIC-HPLC and the resultant clipped PSA peak were collected for analysis.

HIC-HPLC of PSA

5        High-performance hydrophobic interaction chromatography (HIC-HPLC) was performed using a polypropylaspartamide column (PolyLC, distributed by Western Analytical, Temecula, CA). The column was 4.6 X 250 mm in length with a 1000 Å pore size. Samples were applied in 1.5 M ammonium sulfate and eluted with a gradient. Buffer A: 1.2 M sodium sulfate, 25 mM sodium phosphate, pH 6.3, and Buffer B: 50 mM sodium phosphate, 5% v/v 2-propanol. The gradient was 0-35 % B 1 min, 30-80% B 12 min, isocratic at 80% B for 2 min before equilibration in Buffer A. High sensitivity peak detection was obtained with a Varian Model 9070 scanning fluorescence detector using an excitation of 232 nm and emission of 334 nm to detect the tryptophan residues in protein.

10

Amino Acid Sequencing of PSA

15        N-terminal sequence analysis of the samples was performed on a PE-Applied Biosystems Model 492 amino acid sequencer (Perkin-Elmer, Applied Biosystems Division, Foster City, CA). Purified PSA and peaks collected by HIC-HPLC were applied directly to Prosorb cartridges (Perkin-Elmer, Applied Biosystems Division, Foster City, CA), washed 3 X with 0.1 mL 0.01% trifluoroacetic acid and applied to the Model 492  
20        sequencer.

Competition of Streptavidin Microplate Bound PSA-biotin with PSA, inactive PSA and BPSA

PSA was biotinylated with NHS-biotin according to manufacturer's suggested protocol (Pierce, Rockford, IL). 50 ul of anti-PSA monoclonal antibody of various 5 concentrations was incubated with PSA-biotin at 100 ug/L in the streptavidin microplate (Labsystem, Helsinki, Finland) for 2 hr at room temperature. The plate was washed with PBS containing 0.1%tween-20. The goat anti-mouse Ig horseradish peroxidase conjugate (1:5000) was added and incubated for 2 hr. The plate was washed similarly and developed for 1 hr with 100 ul of OPD substrate (Sigma). The reaction was stopped with 4N H<sub>2</sub>SO<sub>4</sub> 10 and absorbance determined at 490 nm. 50 ul of monoclonal antibody at the concentration of representing 50% of the maximum assay response was incubated with 50 ul of various concentrations of PSA, inactive PSA or BPSA for 2 hr in streptavidin microplate, then 50 ul PSA-biotin (100 ug/L) was added for 2 hr. The plate was similarly washed and the bound monoclonal antibody was determined as described above.

15 Preparation and purification of inactive PSA

Purified ACT was obtained from Athens Research and Technology (Athens, GA). 100 ug of purified seminal plasma PSA was incubated with 1 mg of ACT in 500 ul of 50mM Tris (pH 8.0) with 100 mM NaCl for 3 hr at 37°C. The PSA-ACT and inactive PSA were separated by hydrophobic interaction chromatography as described above. 20 Under these conditions PSA-ACT elutes at approximately 8 min and that fraction of PSA which does not react with ACT, i.e., iPSA, continues to elute at 10 min.

Preparation of hybridomas

PS1P351 and PS1R163 were generated from mice immunized with proPSA according to the previously published method for hybridoma preparation.

Generation of Monoclonal Antibodies to BPSA

PSA was purified from seminal plasma according to the described procedure. BPSA was generated from trypsin digestion of PSA and purification of treated material using hydrophobic interaction chromatography (HIC, 8 minute peak) as described. 200 ug 5 of BPSA was incubated with 1 mg each of anti-PSA monoclonal antibodies, PSM773 and PS1R163. The blocked immunogen was purified from unbound Ab and free BPSA by size exclusion chromatography. The mice were immunized once with 50 ug of blocked immunogen in CFA, and twice with 25 ug of blocked immunogen in IFA. The hybridoma was generated according to reported procedures. The culture supernatant was screened for 10 reactivity against BPSA.

Hybridoma Screening Assays

50 ul of culture supernatant was added to the wells of streptavidin microplate (Wallac, Turku, Finland) and 50 ul of biotinylated BPSA at 100 ng/ml was also added. After 1 hr incubation the plate was washed with PBS/0.1% tween-20, then incubated with 15 50 ul per well of goat anti-mouse Ig horseradish peroxidase (1:10,000) diluted in PBS/1% BSA and 0.1% tween-20. After 1 hr incubation, the plate was washed and developed with OPD substrate (Sigma). To determine the specificity of monoclonal antibodies, the reactivity of 100 ng/ml BPSA and 100 ng/ml intact PSA (HIC, 10 minute peak) was compared.

20

**EXAMPLE I**PSA in prostate tissues by HIC-HPLC

The initial observation that a different form of PSA was present in prostate tissue extracts was obtained by HIC-HPLC. Typically, PSA elutes at 10 min under standard HIC-HPLC procedures used in these experiments. A smaller peak of PSA was observed

in some samples, which eluted differently than the main PSA peak. It was further observed that this variant form of PSA was present primarily in the extracted TZ tissues and was less evident in the PZ cancer and non-cancer tissues. **Figure 1** is a high-performance hydrophobic interaction chromatographic (HIC-HPLC) profile of 5 immunoaffinity-purified PSA, isolated from prostate tissues. Three matched tissues from the same prostate were analyzed: transitional zone, TZ; peripheral zone containing 80-100% tumor, PZ-C; and peripheral zone with no cancer, PZ-N.

**Figure 1** shows the comparative profile of the PSA purified from matched prostate tissue. In this sample, the PSA peak eluting at 8 min contains 28% of the total PSA in the 10 TZ extract, while it is present at only 3 and 8% in the PZ-C and PZ-N tissues, respectively. For the purpose of the present invention, the PSA eluting at 8 min has been designated as BPSA. Table 1 shows the percentage of total PSA which is BPSA in 18 matched sets of prostate tissue samples. Ten large volume and 8 small volume prostates are represented.

Table 1 The percentage of BPSA in matched prostate tissues.

15

#	Large Volume Prostate (>50 g)			#	Small Volume Prostate (<25 g)		
	PZ-N	PZ-C	TZ		PZ-N	PZ-C	TZ
1	3.5	5.6	12.0	11	1.7	0.0	6.5
2	3.5	5.6	10.8	12	0.0	0.0	29.5
3	0.0	4.7	5.3	13	3.2	4.0	4.8
4	3.2	13.9	6.6	14	5.0	4.6	19.0
5	9.7	10.7	3.8	15	6.3	1.3	2.3
6	5.3	5.2	9.4	16	5.5	4.9	1.1
7	0.0	2.3	7.6	17	0.9	0.0	1.7
8	4.0	2.5	4.4	18	5.2	2.3	4.4
9	7.5	6.6	13.9				
10	8.3	3.2	28.1				

Since the absolute percentage of BPSA was seen to vary between 1 and 30% of the total PSA in different TZ patient samples, the present invention also examined TURP tissue. The TURP (transurethral resection of the prostate) procedure removes the entire

transitional zone and so an analysis of a TURP extract shows the average level of BPSA throughout the TZ. The TURP procedure is performed on patients with BPH. **Figure 2** shows the HIC-HPLC profile of the PSA purified from TURP tissue. The BPSA elutes at 8 min and the other forms of PSA elute at 10 min. BPSA represents approximately 20% 5 of the total PSA.

Characterization of BPSA from prostate tissue

In order to understand the exact nature of BPSA, prostate tissue was extracted to obtain purified PSA sufficient for further analysis. This tissue was derived from fresh prostatectomy samples but was not characterized as being PZ or TZ tissue, only that it was 10 not cancerous. **Figure 3** shows the HIC-HPLC profile of the PSA purified from this tissue which contains approximately 15% BPSA. The 8 min and 10 min peaks of PSA were collected as shown in **Figure 4**. **Figure 4**, panel A is an HIC-HPLC profile of PSA purified from prostate tissue. The arrows indicate where fractions were collected. **Figure 4B** shows an aliquot of each of these collected peaks re-run individually on HIC-HPLC. 15 **Figure 4** demonstrates that each separately collected fraction has a distinct retention time, which suggests that each contains a different form of PSA. In addition, **Figure 4B** shows that the 8 min BPSA peak is cleanly resolved from the primary peak of PSA which elutes at 10 min.

The 8 min and 10 min PSA peaks were subjected to N-terminal sequencing to 20 determine what clips were present. **Figure 5** shows a histogram of the PSA clips from the different peaks. Four cleavage sites were detected: Ile1, Lysine 145, Lys146 and Lysine 182. The histogram shows the percentage of the total PSA clipped at each site. The clip at Lysine 182 is the most distinctive clip in the 8 min BPSA peak, which is virtually absent in the 10 min peak. The clip at Ile1, which generates PSA beginning with N-

terminus valine, is also lower at 10 min. The clip Ile1 has been observed in the PSA obtained from BPH tissue (13). This clip is not responsible for the shift from 10 min to 8 min (see Figures 9 and 10). The presence of this unusual Ile1 clip almost exclusively in BPSA does suggest that this clip may also be associated with BPH tissue. The clip at 5 Lysine 145, the most common clip found in PSA from seminal plasma, is also significant in the 8 min PSA peak. The Lysine 145 clip is not unique to the 8 min PSA peak, since it is found in the 10 min PSA purified from seminal plasma (see Figures 7 and 8). The clip at Lysine 182 remains distinctive in the BPSA peak, since this clip has not been reported as a primary clip in other studies on the different forms of PSA. It should be noted that 10 serine 183 is the main substrate coordinating amino acid in the substrate binding pocket (15). This is also near the active site residue, serine 189. Thus the clip at Lysine 182 would be expected to disrupt key residues in the enzymatic activity of PSA. This was confirmed by experiments that showed BPSA did not form a complex with ACT (data not shown).

15 Control experiments were performed on tissue extracts to determine how liable the Lysine 182 clips were in tissue extracts. An aliquot of the extract was removed and incubated at 37 °C for 1 hr to determine if any additional internal cleavage at Lysine 182, or elsewhere, was formed *in vitro*. No additional internal cleavage sites were obtained after incubation as determined by HIC-HPLC and N-terminal sequencing (data not shown). This indicates that there is no significant *in vitro* proteolytic cleavage during the 20 extraction and PSA purification procedure and that any observed PSA clips are endogenous to the PSA prior to purification and analysis.

## EXAMPLE II

### Comparison of BPSA to the inactive PSA from seminal plasma

The 8 min PSA peak, which is also called BPSA for the purpose of the present invention, is a distinct form of PSA that is not the same as the inactive forms of PSA 5 previously described in seminal plasma. **Figure 6** shows an HIC-HPLC profile of the PSA purified from pooled seminal plasma. **Figure 6** shows that BPSA (which is inactive) is present at low levels, from 5-9% in seminal plasma PSA preparations. However, BPSA has been characterized above as having a predominant clip at Lysine 182 and this clip has not been described in association with inactive seminal plasma PSA. 40-50 % of seminal 10 plasma PSA is inactive and does not complex with ACT. Thus, the bulk of the inactive seminal plasma PSA is not BPSA. Studies of inactive seminal plasma PSA have not described cleavage at Lysine 182, but have attributed the lack of enzymatic activity to the clip at Lysine 145.

In the current experiments, the inactive forms of seminal plasma PSA were 15 obtained after incubation of seminal plasma PSA with ACT. The PSA that did not complex with ACT is, by definition, inactive PSA (iPSA). PSA was reacted with excess ACT *in vitro*, and the free inactive PSA was purified from PSA-ACT complex by HIC-HPLC (data not shown). For comparative purposes, iPSA does not include the minor fraction of BPSA in whole seminal plasma PSA, since the purpose is to compare the 20 inactive seminal plasma PSA, described by others, to purified BPSA described herein. This large percentage of seminal plasma PSA that does not react with ACT has been hypothesized by others as possibly representing the free form of PSA present in prostate cancer serum (8-10).

**Figure 7** is an HIC-HPLC profile of different types of PSA. Panel A is inactive seminal plasma PSA defined as that fraction of PSA which does not react with ACT. Panel B is HIC-HPLC purified 10 min PSA. Panel C is an HIC-HPLC profile of immunoaffinity purified whole seminal plasma PSA. Panel D is HIC-HPLC purified 5 BPSA. In Figure 7, the HIC-HPLC profile of whole affinity purified PSA is seen in 7C. From this, the 8 min BPSA peak was collected (7D) and the 10 min PSA peak was purified (7B). The 10 min PSA from 7B was incubated with excess ACT, and that fraction of PSA which did not form a complex with ACT, i.e., iPSA, was purified from the PSA-ACT complex and is shown in 7A.

10 **Figure 7A** shows that iPSA elutes at 10 min, the same retention time of the bulk of active PSA from seminal plasma (**Figure 7B**). However, iPSA is distinctly different from BPSA, which is seen in **Figure 7D**. Thus, while the PSA in 7A and 7B appears identical by HIC-HPLC, the PSA in 7B contains a majority of active PSA as indicated by its ability to form an ACT complex and by its lower level of internal clips as seen in **Figure 8**.

15 **Figure 8** is the N-terminal sequence analysis of the PSA peaks in Figure 7. The histogram shows the percentage of the total PSA which is clipped at each of the indicated sites. More importantly, **Figure 8** shows that the main difference between iPSA and BPSA is that BPSA is clipped at Lysine 182.

Thus, BPSA is distinct from iPSA by HIC-HPLC and by internal cleavage sites. In 20 the literature, iPSA has been proposed as the paradigm for the free PSA which may exist in serum. The present invention has shown, however, that BPSA is the form of PSA which is elevated in BPH tissue, and that this form of PSA has the unique property of eluting at 8 min by HIC-HPLC, due to the clip at Lysine 182.

### EXAMPLE III

#### The conversion of PSA to BPSA by in vitro treatment of PSA with trypsin

The unique property of BPSA to elute at 8 min was also demonstrated by *in vitro* experiments where the 10 min HIC-HPLC PSA peak was converted to the 8 min peak.

5 This was accomplished by subjecting purified 10 min PSA to limited trypsin treatment.

Trypsin is a protease which clips at the basic amino acid residues, lysine and arginine.

**Figure 9** shows the HIC-HPLC profile of 10 min PSA before and after trypsin treatment.

After trypsin treatment, a major peak eluting at 8 min is seen, along with two other peaks.

Each of the peaks seen in Figure 9 was sequenced. **Figure 10** is the N-terminal

10 sequencing of the samples in Figure 9. PSA prior to trypsin treatment is indicated as the starting PSA in Figure 10. Since this is seminal plasma PSA, it is seen to be about 30% clipped at Lysine 145, as expected from reports in the literature. Figure 10 shows that

Peak A, the 8 min peak, contains clips at Lysine 182 and Lysine 145, and, to a lesser

extent, Arginine 85—all sites susceptible to cleavage by trypsin. In terms of HIC-HPLC

15 profile, this peak elutes as BPSA. The cleavage pattern is similar to purified native

seminal plasma BPSA which is also shown in Figure 10 for comparison. The main

difference between the artificially generated BPSA and natural BPSA is the absence of

any cleavage at Ile1 in the trypsin-treated sample. Trypsin does not cleave after Ile

residues. Since this form of PSA elutes at 8 min, this further demonstrates that the Ile1

20 clip seen in natural BPSA does not play a part in shifting the retention time from 10 min to

8 min. The two other peaks, B and C, formed after the trypsin treatment, were also

clipped at lysine and arginine sites as seen in Figure 10. Interestingly, peak C is largely

clipped at Lysine 182 only, and still elutes near 10 min. This suggests that either other

conformational changes in the PSA structure are necessary to cause the shift from 10 min

to 8 min, or that Lysine 182 combined with the Lysine 145 clip is necessary to shift the PSA to 8 min.

The treatment of PSA with trypsin demonstrates that it is possible to create *in vitro* a form of PSA which has properties similar to native BPSA. It also demonstrates 5 conclusively that it is the cleavage at the lysine sites which is responsible for the shift from 10 min to 8 min, and not some other post-translational modification, or some conformational change unrelated to the peptide bond cleavages at Lysine 182.

Summary of the clips in different forms of PSA

The clips present in BPSA isolated from prostate tissue, from seminal plasma, as 10 well as BPSA artificially generated by trypsin treatment, can be seen in **Figure 11**. Figure 11 is a summary histogram of N-terminal sequencing of all the major types of purified PSA and BPSA. BPSA from tissue extracts, from seminal plasma and *in vitro* prepared BPSA — all show a similar cleavage pattern. For comparison, the other major types of PSA described earlier are also shown. The Lysine 182 clip distinguishes the BPSA forms 15 from all other types of PSA. This figure demonstrates the unique sequence pattern of BPSA.

It should be noted that, in retrospect, the clips at Lys 185 and Lys 148, as described by Watt et al. (5), may be the same clips at Lys 182 and Lys 145 of the present invention. It is believed that Watt's residue numbers were off by three amino acids. The amino acids 20 from 140-144 appear to be incorrect, and eight completely wrong amino acids were substituted in place of five. Therefore, it appears that Watt's sequence is off three amino acids by showing Lys148 instead of Lys145; and Lys185 instead of Lys182.

Assuming the above belief is correct, Watt, however, has no discussion as to the relative proportion and significance of these clips. In fact, subsequent studies have

focused almost exclusively on the clip at Lysine 145. It is the discovery of the present invention that the novel forms of PSA are distinctly different than other forms of PSA as discussed above.

#### EXAMPLE IV

5 Immunological analysis of BPSA compared to other types of PSA

In addition to HIC-HPLC differences, BPSA was also recognized differently by mAbs generated against seminal plasma purified PSA. **Figure 12** shows a competition assay using six mAbs that recognize different epitopes on PSA. The higher the value, the more poorly the indicated antigen binds to the indicated antibody. The highest binding of 10 these mAbs was towards seminal plasma purified PSA, which is consistent with the fact that this was the immunogen used to develop these mAbs. The HIC-HPLC purified seminal plasma PSA eluting at 10 min had the highest binding to the six monoclonal antibodies tested and so was defined as 100%. The binding of the other types of PSA were compared to this value.

15 In **Figure 12**, the competitive binding of the six monoclonal antibodies to the following antigens is compared: iPSA, BPSA eluting at 8 min, and affinity purified whole PSA. For consistency, each of these forms of PSA was derived from seminal plasma. The HIC-HPLC profile of each form of PSA is shown in **Figure 7**. The competitive binding of the whole PSA is comparable to the HIC-HPLC purified at the 10 min peak of PSA, as 20 expected, since the only difference is the removal of the minor levels of the 8 min BPSA peak. The iPSA is recognized less well by the six mAbs. This may be because iPSA is highly clipped (**Figure 8**) which may result in conformational changes which alters some epitopes.

The purified BPSA is clearly different than the other types of PSA. In particular, the binding of the 399 mAb is significantly reduced compared to the other forms of PSA. Since the major difference between BPSA is the clip at Lysine 182, it is possible that the binding of 399 monoclonal antibody is adversely affected by this clip. **Figure 13** is a 5 competition assay comparing natural forms of BPSA with the BPSA and other forms of PSA obtained from trypsin treatment of PSA. **Figure 13** shows that the trypsin-generated BPSA sample, peak A (Figure 9) gives a similar pattern of reactivity to naturally occurring purified seminal plasma BPSA. Peak C, which contains primarily the clip at Lysine 182 alone, shows a pattern similar to the 8 min peak A. While 399 mAb binds PSA peak C 10 more tightly than PSA peak A, the binding of peak C PSA is still adversely affected. PSA peak C is less tightly bound by 399 monoclonal antibody than iPSA seen in Figure 12, even though iPSA is highly clipped at Lysine 145. Thus, it appears that the clip at 182 is not only essential for the shift to 8 min (Figures 7 and 8), but this clip alone affects the 15 epitope for 399 monoclonal antibody. These results further support the idea that BPSA is a unique form of PSA which can be distinguished from other forms of PSA. This data support the hypothesis that monoclonal antibodies can be generated which recognize BPSA preferentially over other forms of PSA.

#### Discussion

BPSA showed significantly reduced reactivity with two different anti-PSA 20 monoclonal antibodies, PSA399 and PS1P351. There were three other anti-PSA monoclonal antibodies for which the BPSA reactivity was similar to intact PSA reactivity. This finding suggests that, together, the 145 to 146 and 182 to 183 clips change not only the PSA conformation as determined by HIC method, but also change the selective reactivity to some PSA epitopes. The unique structural changes on BPSA may be targets

for generating specific monoclonal antibodies and developing immunoassays useful for detection of BPSA in the biological samples such as serum or tissue.

The six monoclonal antibodies used in this study have been well characterized with various approaches. The approaches included Ab pairing, equimolarity between FPSA and PSA-ACT, binding effect on enzymatic activity, affinity constants (Ka), , and reactivity to proPSA. The characteristics of these monoclonal antibodies are described in

Table 2.

Table 2

<b>Group</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>B/E</b>	<b>A/C</b>
<b>Code/epitope</b>	<b>PSA399</b>	<b>PSM773</b>	<b>PSJ206</b>	<b>PSB999</b>	<b>PS1P351</b>	<b>PS1R163</b>
<b>Ka (M-1)</b>	4.6xE9	1.0xE10	1.1xE9	3.1xE10		
<b>Pairs to</b>	C, D, E A/C	B, D, E B/E	B, C, E B/E	B, C, D A/C	C, D A/C	B, D, E B/E
<b>Presence on fPSA</b>	yes	yes	yes	yes	yes	yes
<b>Presence on PSA-ACT</b>	yes	yes	yes	no	yes	yes
<b>Blocks enzyme activity</b>	100%	100%	0%	100%		
<b>Blocks PSA-ACT formation</b>		85%	0%	100%		
<b>proPSA vs PSA</b>	100%	100%		100%	100%	100%
<b>BPSA vs PSA</b>	45%	100%	100%	80%	50%	100%

Summary

In summary, the novel molecular forms of PSA of the present invention, designated as BPSA, are distinctly different from other forms of PSA which have been described. BPSA is different by HIC-HPLC, N-terminal sequence analysis and antibody binding. The present invention has discovered that BPSA is enriched in prostatic TZ tissue and that BPSA may therefore prove to be a valuable biochemical marker for the discrimination of BPH from prostate cancer. Because the present invention has isolated and purified BPSA away from other forms of PSA, antibodies may be developed in accordance with the present invention. The antibodies of the present invention will 5 discriminate the novel forms of PSA of the present invention in an immunoassay format. The development of an immunoassay can be used to screen large populations of patients 10 with diagnosed BPH and prostate cancer in order to establish the parameters for its use as a serum biomarker.

15

**EXAMPLE V****Generation of Specific Monoclonal Antibodies to BPH Associated Prostate Specific Antigen (BPSA) (and Development of Immunoassay)**

The previous data imply that the conformational change of BPSA molecules may relate to unique immunological properties. Since the unique antigenic site may not be as 20 immuno-dominant as the existing known PSA epitopes, blocking Abs may be useful to mask some of the immunodominant epitopes to allow the immune response against the minor antigenic sites. Based on the previous analysis of binding characteristics described above, PSM773 and PS1R163 demonstrate no change of binding between BPSA and

intact PSA. Therefore these epitopes may be distant to the BPSA unique antigenic sites and are selected as blocking Abs.

Several clones of hybridoma have been generated and all demonstrated preferential reactivity to BPSA as compared to intact PSA reactivity (Table 3).

5

Table 3 Comparison of monoclonal antibody reactivity to BPSA and intact PSA

			<u>Absorbance 490nm</u>
		Clone number	Reactivity to BPSA      Reactivity to PSA
10	PS2C109		9.4      1.0
	PS2C501		9.3      6.5
	PS2C634		8.7      5.0
	PS2C807		9.5      6.6
	PS2C837		2.9      1.5
	+ control*		15.2      14.7
15	no Ab		0.05      0.05

\* PSM773 at 10 ug/ml

PS2C109 showed very good specificity toward BPSA and others were preferentially reactive with BPSA. **Figure 15** shows the comparative data of monoclonal antibody reactivity of PS2C109 to BPSA and PSA. The supernatant of PS2C109 was reanalyzed again with BPSA and PSA during 2ml and freezing stages of cell line and similar results were obtained. Therefore the cell line remains stable during prolonged periods of tissue culture.

The conformational change of BPSA allows biochemical purification, using an approach such as hydrophobic interaction chromatography. There have been no previous reports regarding the generation of specific monoclonal antibodies against PSA which contains the 145-146 and 182-183 clips. The reason for the lack of publications may be 5 because the conformational change on BPSA may not be as immunodominant as other known PSA epitopes. By the use of PSM773 and PS1R163 monoclonal antibodies to block some PSA epitopes, the immune response may be directed to the less immunodominant antigenic site. Since the BPSA is present at only 5-10% in seminal plasma, it is also possible that immunization with pure BPSA resulted in enhanced 10 antibody production to this form of PSA. The availability of purified BPSA also allowed screening of the fusions for mAbs specific for this form of BPSA. The anti-PSA monoclonal antibodies have traditionally been generated against the purified PSA of seminal plasma. The many anti-PSA monoclonal antibodies evaluated against BPSA and whole PSA showed that these Abs either reacted equally with BPSA and PSA or reacted 15 less with BPSA. No Ab with specific or preferential BPSA reactivity was ever identified.

#### EXAMPLE VI

BPSA is generally elevated in the TZ over the other prostate tissues, as shown in Table 1. The TZ was also examined for nodular development since the presence of BPH nodules are considered a physiological property of BPH (Bostwick et al., *supra*). The 20 presence of nodular BPH in the 18 samples was determined in a blinded fashion by histological examination of tissue slices after whole mount pathological processing. Table 3 shows the results of this examination. Samples are listed by decreasing prostate volume.

Table 3 The correlation of %BPSA and BPH nodules in the transition zone

#	Prostate Volume	Peripheral Zone Non-cancer	Peripheral Zone cancer	Transition Zone	BPH nodules
		% BPSA	% BPSA	% BPSA	
1	118	8.33	3.19	28.11	yes
2	90	7.50	6.59	13.87	yes
3	72	3.45	5.60	10.77	yes
4	62	3.99	2.49	4.37	yes
5	60	0.00	2.27	7.56	yes
6	54	9.75	10.74	3.76	no
7	54	5.34	5.24	9.38	yes
8	53	3.47	5.56	11.96	yes
9	53	3.22	13.89	6.62	yes
10	51	0.00	4.73	5.33	no
11	24	5.04	4.63	18.97	yes
12	24	5.55	4.91	1.12	no
13	23	6.25	1.28	2.27	no
14	22	5.18	2.33	4.41	no
15	21	0.94	0.00	1.75	no
16	18	0.00	0.00	29.52	yes
17	17	1.66	0.00	6.51	yes
18	17	3.17	4.03	4.76	no

Figure 16 shows a box plot of the data in Table 3. The %BPSA in each tissue is plotted in two groups, depending on whether the transition zone for each set of tissues contained BPH nodules. The 11 tissues that were positive for BPH nodules in the TZ are compared to the 7 tissues without BPH nodules. The top and bottom of the box denote the 25<sup>th</sup> and 75<sup>th</sup> percentile values; the center bar denotes the mean, and the error bars show the 5<sup>th</sup> and 95<sup>th</sup> percentile values. From Figure 16 it is evident that the %BPSA is more highly elevated in those TZ samples which contain BPH nodules. The TZ samples with BPH nodules contain a mean of 13.4% BPSA, while those tissues without nodules contain

only 3.3% BPSA ( $p<0.008$ ). By contrast, there is no statistical difference between the corresponding PZ-N and PZ-C tissues, whether or not BPH nodules were present in the TZ. Further, the %BPSA in those TZ that contained no BPH nodules is not statistically different than the PZ-N and PZ-C tissues.

5

These results strongly suggest that the %BPSA is associated with the prostatic disease state of BPH, as evidenced by the presence of BPH nodules.

In conclusion, BPSA specific monoclonal antibodies have been developed. Monoclonal antibodies with this type of reactivity will be important to developing specific 10 immunoassay for measurement of BPSA in biological specimens such as serum, seminal fluid and tissue.

The present invention may be embodied in other specific forms without departing from its essential characteristics. The described embodiment is to be considered in all respects only as illustrative and not as restrictive. The scope of the invention is, therefore, 15 indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of the equivalence of the claims are to be embraced within their scope.

Reference List

1. Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., Yuan, J.J., Tetros, J.A., and Andriole, G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. *N Engl J Med.*, 324: 1156-1161, 1991.
2. Oesterling, J.E. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. *J Urol.*, 145: 907-923, 1991.
3. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., and Emond, J. Serum prostate specific antigen as pre-screening test for prostate cancer [see comments]. *J Urol.*, 147: 846-851, 1992.
4. Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D., and Partin, A.W. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. *Crit Rev Clin Lab Sci.*, 35: 275-368, 1998.
5. Watt, K.W.K., Lee, P.J., M'Timkulu, T., Chan, W.P., and Loor, R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. *Proc. Natl. Acad. Sci. USA.*, 83: 3166-3170, 1986.
6. Belanger, A., van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T., Huang, L.H., Poppe, I., and Labrie, F. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. *Prostate*, 27: 187-197, 1995.
7. McCormack, R.T., Rittenhouse, H.G., Finlay, J.A., Sokoloff, R.L., Wang, T.J., Wolfert, R.L., Lilja, H., and Oesterling, J.E. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. *Urology*, 45: 729-744, 1995.
8. Christensson, A., Laurell, C.B., and Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. *Eur. J. Biochem.*, 194: 755-763, 1990.
9. Lilja, H., Christensson, A., Dahlen, U., Matikainen, M.T., Nilsson, O., Pettersson, K., and Lovgren, T. Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with  $\alpha_2$ -antichymotrypsin. *Clin. Chem.*, 37: 1618-1625, 1991.
10. Stenman, U.H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., and Alfthan, O. A complex between prostate specific antigen and  $\alpha_1$ -antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. *Cancer Res.*, 51: 222-226, 1991.
11. Catalona, W.J. Clinical utility of measurements of free and total prostate-specific antigen (PSA) : a review. *Prostate, Supplement* 7: 64-69, 1996.

12. Zhang, W.M., Leinonen, J., Kalkkinen, N., Dowell, B., and Stenman, U.H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. *Clin.Chem.*, *41*: 1567-1573, 1995.
13. Chen, Z., Chen, H., and Stamey, T.A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. *J.Urol.*, *157*: 2166-2170, 1997.
14. Kumar, A., Mikolajczyk, S.D., Goel, A.S., Millar, L.S., and Saedi, M.S. Expression of pro form of Prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. *Cancer Res.*, *in press*: 1997.
15. Villoutreix, B.O., Getzoff, E.D., and Griffin, J.H. A structural model for the prostate disease marker, human prostate-specific antigen. *Protein Sci.*, *3*: 2033-2044, 1994.

WHAT IS CLAIMED IS:

1. A substantially pure and isolated form of prostate specific antigen (PSA) comprising at least one clip at lysine 182 of the amino acid sequence of a mature form of PSA.
2. The substantially pure and isolated form of PSA of claim 1 additionally comprising one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146.
3. The substantially pure and isolated form of PSA of claim 2 consisting of two clips at Lys 145 and Lys 182 of the mature form of PSA.
4. The PSA of claim 1 existing at an elevated level in transition zone prostate tissue.
5. The PSA of claim 1 existing as a component of free PSA in BPH.
6. The PSA of claim 3 being separable from other forms of free PSA by HIC-HPLC technique.
7. An antibody that is preferentially reactive with a form of PSA that comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA.

PCT/US00/09415

8. The antibody of claim 7, wherein the form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146.
9. The antibody of claim 8, wherein the form of PSA consists of two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA.
10. The antibody of claim 7, wherein the antibody is a polyclonal antibody.
11. The antibody of claim 7, wherein the antibody is a monoclonal antibody.
12. The antibody of claim 11, wherein the monoclonal antibody is selected from a group consisting of PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.
13. An immunogen that is capable of eliciting a monoclonal antibody which preferentially binds to a novel form of PSA comprising at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA, wherein the immunogen comprises a form of PSA having at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA.
14. A hybridoma cell line capable of producing a monoclonal antibody that preferentially binds to a novel form of PSA comprising at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA.

15. The hybridoma cell line of claim 14, wherein the monoclonal antibody is selected from a group consisting of monoclonal antibodies PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.

16. A method of producing monoclonal antibodies which preferentially binds to a novel form of PSA comprising at least one clip at Lys 182 of a mature form of PSA, the method comprising steps of:

(a) immunizing a mouse with a novel form of PSA; and  
(b) producing monoclonal antibodies from the immunized mouse by employing a monoclonal antibody technique, wherein the monoclonal antibodies preferentially bind to the novel form of PSA compared to other forms of free PSA.

17. The method of claim 16, wherein the monoclonal antibody produced by step (b) is selected from a group consisting of PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.

18. A method of detecting, or determining in a sample, a form of prostate specific antigen (PSA) comprising at least one clip at lysine 182 of the amino acid sequence of a mature form of PSA, the method comprising the steps of:

(a) contacting an amount of an agent which specifically binds to the form of PSA to be detected with the sample under a condition that allows the formation of a binary complex comprising the agent and the form of PSA; and  
(b) detecting or determining the presence or amount of the complex.

19. The method of claim 18, wherein the sample is a sample of human physiological fluid.
20. The method of claim 19, wherein the human physiological fluid is serum, seminal plasma, urine or plasma.
21. The method of claim 18, wherein the agent is an antibody.
22. The method of claim 21, wherein the antibody is a monoclonal antibody.
23. The method of claim 22, wherein the monoclonal antibody is selected from a group consisting of PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.
24. The method of claim 19, wherein the agent is an antibody and wherein the antibody is attached to a solid phase.
25. The method of claim 19, wherein the agent is an antibody and wherein in step (b) the antibody comprises a detectable label or binds to a detectable label to form a detectable ternary complex.
26. The method of claim 18, wherein the sample is a mammalian tissue sample.

27. The method of claim 26, wherein the agent is an antibody.
28. The method of claim 26, wherein in step (b), the complex is detected by a second agent which comprises a detectable label or which binds to a detectable label to form a detectable ternary complex.
29. The method of claim 28, wherein the second agent is an antibody.
30. The method of claim 26, wherein the mammalian tissue is a human prostate tissue.
31. The method of claim 18, wherein the form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146.
32. The method of claim 18, wherein the form of PSA consists of two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA.
33. A test kit for detecting or determining in a sample the form of PSA comprising at least one clip at lysine 182 of the amino acid sequence of a mature form of PSA, the kit comprising a known amount of an agent which preferentially binds to the form of PSA to be detected, wherein the agent is detectably labeled or binds to a detectable label.

34. The test kit of claim 33, wherein the sample is a sample of human physiological fluid.
35. The test kit of claim 33, wherein the agent comprises an antibody that preferentially binds to the form of PSA.
36. The test kit of claim 35 further comprising a solid phase capable of having the antibody attached thereto.
37. The test kit of claim 33, wherein the sample is a mammalian tissue sample.
38. The test kit of claim 37, wherein the agent is an antibody.
39. The test kit of claim 38, wherein the antibody is a monoclonal antibody.
40. The test kit of claim 33, wherein the agent is a monoclonal antibody selected from a group consisting of PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.
41. The test kit of claim 33, wherein the form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146.

42. The test kit of claim 41, wherein the form of PSA consists of two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA.

43. A method for distinguishing benign prostate hyperplasia from prostate cancer comprising:

- (a) contacting an amount of an agent, which preferentially binds to a form of PSA comprising at least one clip at lysine 182 of the amino acid sequence of a mature form of PSA, with a sample obtained from a human containing the form of PSA under a condition sufficient to allow the formation of a binary complex comprising the agent and the form of PSA; and
- (b) determining the amount of the complex in the sample and correlating the amount of the complex to the presence or absence of benign prostatic hyperplasia or prostate cancer in the human.

44. The diagnostic method of claim 43, wherein the form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146.

45. The method of claim 50, wherein the form of PSA comprises two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA.

46. The method of claim 43, wherein the sample is a sample of physiological fluid.

47. The method of claim 43, wherein the sample is a mammalian tissue sample.
48. The method of claim 43, wherein the agent is an antibody.
49. The diagnostic method of claim 48, wherein the agent is a monoclonal antibody.
50. The method of claim 49, wherein the monoclonal antibody is selected from a group consisting of PS2C109, PS2C501, PS2C634, PS2C807, and PS2C837.

1/10




Fig. 1






Fig. 2



*Fig. 3*



*Fig. 4*

3/10




Fig. 5




Fig. 6

4/10




Fig. 7

5/10




Fig. 8




Fig. 9

6/10




Fig. 10

7/10




Fig. 11

8/10




Fig. 12




Fig. 13

9/10

## PSA SEQUENCE

1  
IVGGWECEKH SQPWQVLVAS RGRAVCGGVL VHPQWVLTAA 40

HCIRNKSIL LGRHSLFHPE DTGQVFQVSH SFPHPLYDMS 80

LLKNRFLRPG DDSSHDLMLL RLSEPAELTD AVKVMLDLPTQ 120

145  
EPALGTTCYA SGWGSIEPEE FLTPKKLQCV DLHVISNDVC 160

182  
AQVHPQKVTK FMLCAGRWTG GKSTCSGDSG GPLVCNGVLQ 200

GITSWGSEPC ALPERPSLYT KVVHYRKWIK DTIVANP 237

*Fig. 14*

10/10




Fig. 15




Fig. 16